Table 1.

IL-23/IL-23R targeted therapeutics for psoriasis and PsA

Drug name (Reference)	Sponsor	Target	Type	Dose (mg)	Side effects	Clinical Development Status
Ustekinumab [84]	Janssen Biotech	IL-23p40	Fully human IgG1κ monoclonal antibody	45 90	High risks infection and cancer	FDA approval (2009)
Briakinumab [75]	Abbott Laboratories	IL-23p40	Fully human IgG1 monoclonal antibody	100 200	Serious infection and cancer	FDA withdraw (2017)
Tildrakizumab [87]	Sun Pharma and Merck & Co. Inc	IL-23p19	Humanised, IgG1κ mono antibody	100 200	Non reported	FDA approval (2017)
Guselkumab [91]	Janssen	IL-23p19	Fully human IgG1λ monoclonal antibody	100	Non reported	FDA approval (2017)
Risankizumab [92]	Abb Vie Inc	IL-23p19	Fully human IgG1 monoclonal antibody	90 180	Non reported	Phase III Clinical trial